ANTAGONISTS OF GROWTH FACTORS OF VASCULAR ENDOTHELIAL CELLS.

摘要

Use of an hVEGF antagonist in the preparation of a medicament for the treatment of age-related macular degeneration in a human patient, wherein the hVEGF antagonist comprises the amino acid sequence of the extracellular domain of an hVEGFr. 2 Use according to claim 1, wherein the hVEGFr is the flt receiver or the flk-1 receiver (also referred to as KDR). 3. Use according to claim 1 or claim 2, wherein the transmembrane and cytoplasmic domains of hVEGFr are deleted. 4. Use according to any preceding claim 1, wherein the hVEGF antagonist is a fusion protein further comprising a non-hVEGFr polymer or polypeptide. 5. Use according to claim 4, wherein the non-hVEGFr polypeptide is an immunoglobulin. 6. Use according to claim 5, wherein the extracellular domain of hVEGFr is replaced with the Fv domain of an immunoglobulin light or heavy chain. 7. Use according to claim 6, wherein the Fv domain is derived from an immunoglobulin heavy chain. 8. Use according to claim 7, wherein the C-terminal end of the extracellular domain of the receptor is covalently linked to the amino-terminal end of the CH1, hinge, CH2 of the heavy chain. 9. Use according to claim 4, wherein the hVEGFr is conjugated to a non-protein polymer. 10. Use according to claim 9, wherein the non-protein polymer is polyethylene glycol.